Franklin Street Advisors Inc. NC Raises Holdings in Bristol-Myers Squibb (NYSE:BMY)

Franklin Street Advisors Inc. NC lifted its position in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 7,223.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 347,402 shares of the biopharmaceutical company's stock after purchasing an additional 342,658 shares during the period. Bristol-Myers Squibb comprises about 1.3% of Franklin Street Advisors Inc. NC's portfolio, making the stock its 26th biggest holding. Franklin Street Advisors Inc. NC's holdings in Bristol-Myers Squibb were worth $19,649,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in the stock. Wealth Enhancement Advisory Services LLC raised its position in Bristol-Myers Squibb by 1.1% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 354,161 shares of the biopharmaceutical company's stock worth $18,324,000 after acquiring an additional 3,827 shares during the period. Partnership Wealth Management LLC raised its position in Bristol-Myers Squibb by 6.3% during the fourth quarter. Partnership Wealth Management LLC now owns 27,867 shares of the biopharmaceutical company's stock worth $1,576,000 after acquiring an additional 1,658 shares during the period. Legacy Private Trust Co. raised its position in Bristol-Myers Squibb by 3.3% during the fourth quarter. Legacy Private Trust Co. now owns 9,751 shares of the biopharmaceutical company's stock worth $552,000 after acquiring an additional 310 shares during the period. First Hawaiian Bank raised its position in Bristol-Myers Squibb by 3.5% during the fourth quarter. First Hawaiian Bank now owns 50,198 shares of the biopharmaceutical company's stock worth $2,839,000 after acquiring an additional 1,675 shares during the period. Finally, InvesTrust acquired a new position in Bristol-Myers Squibb during the fourth quarter worth $6,466,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Bristol-Myers Squibb Stock Down 1.7 %

Shares of BMY traded down $0.97 during midday trading on Friday, reaching $55.84. The stock had a trading volume of 9,677,613 shares, compared to its average volume of 10,010,127. The company has a market cap of $113.25 billion, a price-to-earnings ratio of -15.55, a PEG ratio of 15.20 and a beta of 0.45. The company's fifty day simple moving average is $57.41 and its two-hundred day simple moving average is $51.34. Bristol-Myers Squibb has a 1-year low of $39.35 and a 1-year high of $61.08. The company has a debt-to-equity ratio of 2.83, a current ratio of 1.24 and a quick ratio of 1.09.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.80 earnings per share for the quarter, beating analysts' consensus estimates of $1.49 by $0.31. The company had revenue of $11.89 billion for the quarter, compared to analysts' expectations of $11.26 billion. Bristol-Myers Squibb had a positive return on equity of 11.94% and a negative net margin of 15.30%. Bristol-Myers Squibb's quarterly revenue was up 8.4% on a year-over-year basis. During the same period last year, the firm earned $2.00 earnings per share. Equities research analysts expect that Bristol-Myers Squibb will post 0.93 earnings per share for the current year.

Bristol-Myers Squibb Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, February 3rd. Stockholders of record on Friday, January 3rd will be given a dividend of $0.62 per share. This is a boost from Bristol-Myers Squibb's previous quarterly dividend of $0.60. This represents a $2.48 annualized dividend and a dividend yield of 4.44%. The ex-dividend date of this dividend is Friday, January 3rd. Bristol-Myers Squibb's dividend payout ratio is currently -69.08%.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on BMY. UBS Group upped their target price on shares of Bristol-Myers Squibb from $50.00 to $54.00 and gave the stock a "neutral" rating in a report on Wednesday, October 9th. BMO Capital Markets upped their target price on shares of Bristol-Myers Squibb from $57.00 to $61.00 and gave the stock a "market perform" rating in a report on Tuesday, November 12th. Barclays upped their target price on shares of Bristol-Myers Squibb from $42.00 to $43.00 and gave the stock an "underweight" rating in a report on Monday, October 7th. TD Cowen upped their price objective on shares of Bristol-Myers Squibb from $53.00 to $59.00 and gave the company a "hold" rating in a report on Monday, October 7th. Finally, Wolfe Research assumed coverage on shares of Bristol-Myers Squibb in a report on Friday, November 15th. They issued a "peer perform" rating for the company. Two investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, four have issued a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, Bristol-Myers Squibb presently has an average rating of "Hold" and a consensus target price of $56.27.

Insider Transactions at Bristol-Myers Squibb

In related news, EVP Samit Hirawat acquired 1,830 shares of Bristol-Myers Squibb stock in a transaction on Friday, November 1st. The stock was purchased at an average cost of $54.67 per share, with a total value of $100,046.10. Following the purchase, the executive vice president now directly owns 62,109 shares in the company, valued at approximately $3,395,499.03. The trade was a 3.04 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Phil M. Holzer sold 700 shares of the company's stock in a transaction that occurred on Monday, November 4th. The shares were sold at an average price of $55.62, for a total value of $38,934.00. Following the sale, the senior vice president now directly owns 11,760 shares of the company's stock, valued at approximately $654,091.20. This represents a 5.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.09% of the company's stock.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.